Global Triamcinolone Revenue Is Nearly 791 M USD In 2017
Thursday, 01 Nov, 2018
Triamcinolone is an intermediate-acting synthetic glucocorticoid given orally, by injection, by inhalation, or as a topical ointment or cream.
Triamcinolone is used to treat a number of different medical conditions, such as eczema, lichen sclerosus, psoriasis, arthritis, allergies, ulcerative colitis, lupus, sympathetic ophthalmia, temporal arteritis, uveitis, ocular inflammation, keloids, urushiol-induced contact dermatitis, aphthous ulcers (usually as triamcinolone acetonide), visualization during vitrectomy and the prevention of asthma attacks..
In the last several years, global market of Triamcinolone developed stably, with an average growth rate of 0.99%. In 2017, global revenue of Triamcinolone is nearly 791 M USD; the actual sales are nearly 200 M Units.
The classification of Triamcinolone includes Cream, Injection, Inhalation and Others Type. And the sales proportion of Cream in 2017 is about 43%, and the proportion is decreasing trend from 2013 to 2018.
Triamcinolone is widely sales in Hospitals, Drugstores and Others. The most proportion of Triamcinolone is sales in Hospitals, and the consumption proportion is about 45% in 2017.
North America is the largest consumption place, with a revenue market share nearly 43% in 2017. Following North America, Europe is the second largest consumption place with the revenue market share of 36%.
Market competition is intense. Sanofi, Bristol-Myers Squibb, J&J, Mylan are the leaders of the industry. They hold the key technologies and patents, with high-end customers. They have formed global market channel of the industry. However, with the future expanding market, there will be more manufacturers in the future.